Autoimmunity and pulmonary hypertension: A perspective

European Respiratory Journal

Volumn 26, Issue 6, 2005, Pages 1110-1118

  Nicolls, Mark R ^a   Taraseviciene Stewart, L ^a   Rai, P R ^a   Badesch, D B ^a   Voelkel, N F ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Auto antibodies; Autoimmunity; Endothelium; Immune regulation; Immune tolerance; Pulmonary hypertension

Indexed keywords

AUTOANTIBODY; PROSTANOID;

ANTIBODY PRODUCTION; APOPTOSIS; AUTOIMMUNITY; B LYMPHOCYTE; CONNECTIVE TISSUE DISEASE; DISEASE SEVERITY; ENDOTHELIUM CELL; HELPER CELL; HUMAN; IMMUNE INJURY; IMMUNOLOGICAL TOLERANCE; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; T LYMPHOCYTE; VASCULAR ENDOTHELIUM; VIRUS INFECTION;

ADULT; AGE DISTRIBUTION; AGED; AUTOIMMUNE DISEASES; AUTOIMMUNITY; BIOPSY, NEEDLE; COMORBIDITY; FEMALE; HUMANS; HYPERTENSION, PULMONARY; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SURVIVAL ANALYSIS;

EID: 29244486514     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.05.00045705     Document Type: Review

References (110)

1. Mukerjee D, St George D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003; 62: 1088-1093.
2. Fagan KA, Badesch DB. Pulmonary hypertension associated with connective tissue disease. Prog Cardiovasc Dis 2002; 45: 225-234.
3. Zandman-Goddard G, Shoenfeld Y. HIV and auto-immunity. Autoimmun Rev 2002; 1: 329-337.
4. Parravinci C, Corbellino M, Paulli M, et al. Expression of a virus-derived cytokine, KSHV vIL-6, in HIV-seronegative Castleman's disease. Am J Pathol 1997; 151: 1517-1522.
5. Kemeny L, Kiss M, Gyulai R, et al. Human herpesvirus 8 in classic Kaposi sarcoma. Acta Microbiol Immunol Hung 1996; 43: 391-395.
6. Onji M, Doi Y, Miyaoka H, Masumoto T, Horiike N, Ohta Y. Serum levels of soluble CD4 and CD8 in patients with chronic viral hepatitis. Hepatogastroenterology 1994; 41: 377-379.
7. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: Suppl. 12, 5S-12S.
8. Proceedings of the 3rd World Symposium on Pulmonary Arterial Hypertension. Venice, Italy, June 23-25, 2003. J Am Coll Cardiol 2004; 43: Suppl. 12, 1S-90S.
9. Veeraraghavan S, Koss MN, Sharma OP. Pulmonary veno-occlusive disease. Curr Opin Pulm Med 1999; 5: 310-313.
10. Voelkel NF, Cool C. Pathology of pulmonary hypertension. Cardiol Clin 2004; 22: 343-351.
11. Tucker A, Rhodes J. Role of vascular smooth muscle in the development of high altitude pulmonary hypertension: an interspecies evaluation. High Alt Med Biol 2001; 2: 173-189.
12. Anand IS, Wu T. Syndromes of subacute mountain sickness. High Alt Med Biol 2004; 5: 156-170.
13. Stenmark KR, Orton EC, Reeves JT, et al. Vascular remodeling in neonatal pulmonary hypertension. Role of the smooth muscle cell. Chest 1988; 93: Suppl. 3, 127S-133S.
14. Cullinane C, Cox PN, Silver MM. Persistent pulmonary hypertension of the newborn due to alveolar capillary dysplasia. Pediatr Pathol 1992; 12: 499-514.
15. Heath D. Pulmonary hypertension in pulmonary parenchymal disease. Cardiovasc Clin 1972; 4: 79-96.
16. Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994; 144: 275-285.
17. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: Suppl. 12, 13S-24S.
18. Cool CD, Rai PR, Yeager ME, et al. Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med 2003; 349: 1113-1122.
19. Boyer O, Saadoun D, Abriol J, et al. CD4+CD25+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis. Blood 2004; 103: 3428-3430.
20. Eddleston AL. Hepatitis C infection and autoimmunity. J Hepatol 1996; 24: Suppl. 2, 55-60.
21. Panasiuk A, Prokopowicz D, Zak J, Wysocka J. Peripheral blood T, B, and NK cells in relation to histological hepatitis activity and fibrosis stage in chronic hepatitis C. Hepatogastroenterology 2003; 50: 178-182.
22. Degiannis D, Seibold JR, Czarnecki M, Raskova J, Raska K Jr. Soluble and cellular markers of immune activation in patients with systemic sclerosis. Clin Immunol Immunopathol 1990; 56: 259-270.
23. Ingegnoli F, Trabattoni D, Saresella M, Fantini F, Clerici M. Distinct immune profiles characterize patients with diffuse or limited systemic sclerosis. Clin Immunol 2003; 108: 21-28.
24. Crispin JC, Martinez A, Alcocer-Varela J. Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 2003; 21: 273-276.
25. Liu MF, Wang CR, Fung LL, Wu CR. Decreased CD4+CD25+ T cells in peripheral blood of patients with systemic lupus erythematosus. Scand J Immunol 2004; 59: 198-202.
26. Benveniste O, Cherin P, Maisonobe T, et al. Severe perturbations of the blood T cell repertoire in polymyositis, but not dermatomyositis patients. J Immunol 2001; 167: 3521-3529.
27. Covas MI, Esquerda A, Garcia-Rico A, Mahy N. Peripheral blood T-lymphocyte subsets in autoimmune thyroid disease. J Investig Allergol Clin Immunol 1992; 2: 131-135.
28. Mandl T, Bredberg A, Jacobsson LT, Manthorpe R, Henriksson G. CD4+ T-lymphocytopenia - a frequent finding in anti-SSA antibody seropositive patients with primary Sjogren's syndrome. J Rheumatol 2004; 31: 726-728.
29. Hoeper MM, Niedermeyer J, Hoffmeyer F, Flemming P, Fabel H. Pulmonary hypertension after splenectomy? Ann Intern Med 1999; 130: 506-509.
30. Korniszewski L, Kurzyna M, Stolarski B, Torbicki A, Smerdel A, Ploski R. Fatal primary pulmonary hypertension in a 30-yr-old female with APECED syndrome. Eur Respir J 2003; 22: 709-711.
31. Heath D, Yacoub M. Lung mast cells in plexogenic pulmonary arteriopathy. J Clin Pathol 1991; 44:1003-1006.
32. Yanai-Landau H, Amital H, Bar-Dayan Y, et al. Autoimmune aspects of primary pulmonary hypertension. Pathobiology 1995; 63: 71-75.
33. Karmochkine M, Cacoub P, Dorent R, et al. High prevalence of antiphospholipid antibodies in precapillary pulmonary hypertension. J Rheumatol 1996; 23: 286-290.
34. Tanaka E, Harigai M, Tanaka M, Kawaguchi Y, Hara M, Kamatani N. Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol 2002; 29: 282-287.
35. Couper JJ. Environmental triggers of type 1 diabetes. J Paediatr Child Health 2001; 37: 218-220.
36. Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 1996; 98: 785-792.
37. Wusirika R, Ferri C, Marin M, et al. The assessment of anti-endothelial cell antibodies in scleroderma-associated pulmonary fibrosis. A study of indirect immunofluorescent and western blot analysis in 49 patients with scleroderma. Am J Clin Pathol 2003; 120: 596-606.
38. Negi VS, Tripathy NK, Misra R, Nityanand S. Anti-endothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. J Rheumatol 1998; 25: 462-466.
39. Vercellotti GM. Effects of viral activation of the vessel wall on inflammation and thrombosis. Blood Coagul Fibrinolysis 1998; 9: Suppl. 2, S3-S6.
40. Longo F, Saletta S, Lepore L, Pennesi M. Localized scleroderma after infection with Epstein-Barr virus. Clin Exp Rheumatol 1993; 11: 681-683.
41. Magro CM, Nuovo G, Ferri C, Crowson AN, Giuggioli D, Sebastiani M. Parvoviral infection of endothelial cells and stromal fibroblasts: a possible pathogenetic role in scleroderma. J Cutan Pathol 2004; 31: 43-50.
42. Ferri C, Longombardo G, Mugnaini P. Hepatitis E virus and systemic sclerosis. QJM 1998; 91: 375.
43. Ferri C, Zakrzewska K, Longombardo G, et al. Parvovirus B19 infection of bone marrow in systemic sclerosis patients. Clin Exp Rheumatol 1999; 17: 718-720.
44. Harel L, Straussberg R, Rudich H, Cohen AH, Amir J. Raynaud's phenomenon as a manifestation of parvovirus; B19 infection: case reports and review of parvovirus B19 rheumatic and vasculitic syndromes. Clin Infect Dis 2000; 30: 500-503.
45. Abu-Shakra M, Sukenik S, Buskila D. Systemic sclerosis: another rheumatic disease associated with hepatitis C virus infection. Clin Rheumatol 2000; 19: 378-380.
46. Hamamdzic D, Kasman LM, LeRoy EC. The role of infectious agents in the pathogenesis of systemic sclerosis. Curr Opin Rheumatol 2002; 14: 694-698.
47. Neidhart M, Kuchen S, Distler O, et al. Increased serum levels of antibodies against human cytomegalovirus and prevalence of autoantibodies in systemic sclerosis. Arthritis Rheum 1999; 42: 389-392.
48. Vaughan JH, Shaw PX, Nguyen MD, et al. Evidence of activation of 2 herpesviruses, Epstein-Barr virus and cytomegalovirus, in systemic sclerosis and normal skins. J Rheumatol 2000; 27: 821-823.
49. Carapeto FJ, Winkelmann RK. Peripheral blood lymphocyte distribution in scleroderma. Dermatologica 1975; 151: 228-235.
50. Barnett AJ, Tait BD, Barnett MA, Toh BH. T lymphocyte subset abnormalities and HLA antigens in scleroderma (systemic sclerosis). Clin Exp Immunol 1989; 76: 24-29.
51. Sato S, Fujimoto M, Hasegawa M, Takehara K. Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 2004; 50: 1918-1927.
52. Carreira PE. Pulmonary hypertension in autoimmune rheumatic diseases. Autoimmun Rev 2004; 3: 313-320.
53. Voelkel NF, Tuder RM. Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. Eur Respir J 1995; 8: 2129-2138.
54. Harrison NK, Myers AR, Corrin B, et al. Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis 1991; 144: 706-713.
55. Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J 2003; 22: 358-363.
56. Nishizuka Y, Sakakura T. Thymus and reproduction: sex-linked dysgenesia of the gonad after neonatal thymectomy in mice. Science 1969; 166: 753-755.
57. Penhale WJ, Farmer A, McKenna RP, Irvine WJ. Spontaneous thyroiditis in thymectomized and irradiated Wistar rats. Clin Exp Immunol 1973; 15: 225-236.
58. Sakaguchi S, Takahashi T, Nishizuka Y. Study on cellular events in postthymectomy autoimmune oophoritis in mice. I. Requirement of Lyt-1 effector cells for oocytes damage after adoptive transfer. J Exp Med 1982; 156: 1565-576.
59. Penhale WJ, Irvine WJ, Inglis JR, Farmer A. Thyroiditis in T cell-depleted rats: suppression of the autoallergic response by reconstitution with normal lymphoid cells. Clin Exp Immunol 1976; 25: 6-16.
60. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004; 22: 531-562.
61. Shih FF, Mandik-Nayak L, Wipke BT, Allen PM. Massive thymic deletion results in systemic autoimmunity through elimination of CD4+ CD25+ T regulatory cells. J Exp Med 2004; 199: 323-335.
62. Bystry RS, Aluvihare V, Welch KA, Kallikourdis M, Betz AG. B cells and professional APCs recruit regulatory T cells via CCL4. Nat Immunol 2001; 2: 1126-1132.
63. Seo SJ, Fields ML, Buckler JL, et al. The impact of T helper and T regulatory cells on the regulation of anti-double-stranded DNA B cells. Immunity 2002; 16: 535-546.
64. Curotto de Lafaille MA, Muriglan S, et al. Hyper immunoglobulin E response in mice with monoclonal populations of B and T lymphocytes. J Exp Med 2001; 194: 1349-1359.
65. Tsubata T, Wu J, Honjo T. B-cell apoptosis induced by antigen receptor crosslinking is blocked by a T-cell signal through CD40. Nature 1993; 364: 645-648.
66. Lafaille JJ. The role of helper T cell subsets in autoimmune diseases. Cytokine Growth Factor Rev 1998; 9: 139-151.
67. Taraseviciene-Stewart L, Kasahara Y, Alger L, et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 2001; 15: 427-438.
68. Renaudineau Y, Dugue C, Dueymes M, Youinou P. Antiendothelial cell antibodies in systemic lupus erythematosus. Autoimmun Rev 2002; 1: 365-372.
69. Sasaki N, Kurose A, Inoue H, Sawai T. [A possible role of anti-endothelial cell antibody in the sera of MCTD patients on pulmonary vascular damage relating to pulmonary hypertension]. Ryumachi 2002; 42: 885-894.
70. Quismorio FP Jr, Sharma O, Koss M, et al. Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. Semin Arthritis Rheum 1984; 13: 349-359.
71. Nakagawa N, Osanai S, Ide H, et al. Severe pulmonary hypertension associated with primary Sjogren's syndrome. Intern Med 2003; 42: 1248-1252.
72. Papo T, Piette JC, Legac E, et al. T lymphocyte subsets in primary antiphospholipid syndrome. J Rheumatol 1994; 21: 2242-2245.
73. Ramos-Casals M, Cervera R, Lagrutta M, et al. Clinical features related to antiphospholipid syndrome in patients with chronic viral infections (hepatitis C virus/HIV infection): description of 82 cases. Clin Infect Dis 2004; 38: 1009-1016.
74. Raschi E, Testoni C, Borghi MO, Fineschi S, Meroni PL. Endothelium activation in the anti-phospholipid syndrome. Biomed Pharmacother 2003; 57: 282-286.
75. Riboldi P, Gerosa M, Raschi E, Testoni C, Meroni PL. Endothelium as a target for antiphospholipid antibodies. Immunobiology 2003; 207: 29-36.
76. Cheng HM, Hu C. Presence of IgG antiphospholipid autoantibody in nude mice. J Rheumatol 1995; 22: 2006-2007.
77. Karulin AY, Hesse MD, Yip HC, Lehmann PV. Indirect IL-4 pathway in type 1 immunity. J Immunol 2002; 168: 545-553.
78. Sherman MA. The role of STAT6 in mast cell IL-4 production. Immunol Rev 2001; 179: 48-56.
79. Erb KJ, Ruger B, von Brevern M, Ryffel B, Schimpl A, Rivett K. Constitutive expression of interleukin (IL)-4 in vivo causes autoimmune-type disorders in mice. J Exp Med 1997; 185: 329-339.
80. Ong C, Wong C, Roberts CR, Teh HS, Jirik FR. Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma. Eur J Immunol 1998; 28: 2619-2629.
81. Ong CJ, Ip S, Teh SJ, et al. A role for T helper 2 cells in mediating skin fibrosis in tight-skin mice. Cell Immunol 1999; 196: 60-68.
82. Kodera T, McGaha TL, Phelps R, Paul WE, Bona CA. Disrupting the IL-4 gene rescues mice homozygous for the tight-skin mutation from embryonic death and diminishes TGF-beta production by fibroblasts. Proc Natl Acad Sci USA 2002; 99: 3800-3805.
83. Tucker A, McMurtry IF, Alexander AF, Reeves JT, Grover RF. Lung mast cell density and distribution in chronically hypoxic animals. J Appl Physiol 1977; 42: 174-178.
84. Zhu YJ, Kradin R, Brandstetter RD, Staton G, Moss J, Hales CA. Hypoxic pulmonary hypertension in the mast cell-deficient mouse. J Appl Physiol 1983; 54: 680-686.
85. Voelkel NF, Kruse HP. Disodium cromoglycat for symptomatic therapy of generalized mastocytosis. Inn Med 1977; 4: 325-330.
86. Castells MC. Mastocytosis: classification, diagnosis, and clinical presentation. Allergy Asthma Proc 2004; 25: 33-36.
87. Miyata M, Sakuma F, Ito M, Ohira H, Sato Y, Kasukawa R. Athymic nude rats develop severe pulmonary hypertension following monocrotaline administration. Int Arch Allergy Immunol 2000; 121: 246-252.
88. Benoist C, Mathis D. Mast cells in autoimmune disease. Nature 2002; 420: 875-878.
89. Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB. Mast cells: a cellular link between auto-antibodies and inflammatory arthritis. Science 2002; 297: 1689-692.
90. Humbert M, Monti G, Brenot F, et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995; 151: 1628-631.
91. Newman JH, Wheeler L, Lane KB, et al. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med 2001; 345: 319-324.
92. Massague J, Chen YG. Controlling TGF-beta signaling. Genes Dev 2000; 14: 627-644.
93. Hager-Theodorides AL, Outram SV, Shah DK, et al. Bone morphogenetic protein 2/4 signaling regulates early thymocyte differentiation. J Immunol 2002; 169: 5496-5504.
94. Graf D, Nethisinghe S, Palmer DB, Fisher AG, Merkenschlager M. The developmentally regulated expression of twisted gastrulation reveals a role for bone morphogenetic proteins in the control of T cell development. J Exp Med 2002; 196: 163-171.
95. Tsai PT, Lee RA, Wu H. BMP4 acts upstream of FGF in modulating thymic stroma and regulating thymopoiesis. Blood 2003; 102: 3947-3953.
96. Ishisaki A, Yamato K, Hashimoto S, et al. Differential inhibition of Smad6 and Smad7 on bone morphogenetic protein- and activin-mediated growth arrest and apoptosis in B cells. J Biol Chem 1999; 274: 13637-13642.
97. Yamato K, Hashimoto S, Imamura T, et al. Activation of the p21(CIP1/WAF1) promoter by bone morphogenetic protein-2 in mouse B lineage cells. Oncogene 2001; 20: 4383-4392.
98. Nakayama N, Lee J, Chiu L. Vascular endothelial growth factor synergistically enhances bone morphogenetic protein-4-dependent lymphohematopoietic cell generation from embryonic stem cells in vitro. Blood 2000; 95: 2275-2283.
99. Tuder RM, Radisavljevic Z, Shroyer KR, Polak JM, Voelkel NF. Monoclonal endothelial cells in appetite suppressant-associated pulmonary hypertension. Am J Respir Crit Care Med 1998; 158: 1999-2001.
100. Voelkel NF, Cool C, Lee SD, Wright L, Geraci MW, Tuder RM. Primary pulmonary hypertension between inflammation and cancer. Chest 1998; 114: Suppl. 3, 225S-230S.
101. Tuder RM, Cool CD, Yeager M, Taraseviciene-Stewart L, Bull TM, Voelkel NF. The pathobiology of pulmonary hypertension. Endothelium. Clin Chest Med 2001; 22: 405-418.
102. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115:343-349.
103. Badesch DB, McLaughlin VV, Delcroix M, et al. Prostanoid, therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: Suppl. 12, 56S-61S.
104. Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997; 84: 223-243.
105. MacGregor AJ, Canavan R, Knight C, et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) 2001; 40: 453-459.
106. Sackner MA, Akgun N, Kimbel P, Lewis DH. The pathophysiology of scleroderma involving the heart and respiratory system. Ann Intern Med 1964; 60: 611-630.
107. Salerni R, Rodnan GP, Leon DF, Shaver JA. Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma). Ann Intern Med 1977; 86: 394-399.
108. Ungerer RG, Tashkin DP, Furst D, Clements PJ, Gong H Jr, Bein M. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med 1983; 75: 65-74.
109. Wilson L. Cost-of-illness of scleroderma: the case for rare diseases. Semin Arthritis Rheum 1997; 27: 73-84.
110. Sanchez O, Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary hypertension secondary to connective tissue diseases. Thorax 1999; 54: 273-277.